The day of dosing cancer patients with Kevetrin is drawing near according to news this morning from Cellceutix Corporation (OTCBB: CTIX). The Beverly, Massachusetts-based company said today that clinical trials for their novel anti-cancer drug have gone active at Harvard’s Dana-Farber Cancer Center and partner Beth Israel Deaconess Medical Center. Dosing should begin within Read More

There is starting to be a steady buzz across the web about Cellceutix Corporation (OTCBB: CTIX) and its novel cancer drug, Kevetrin™.  For starters, the p53-activating drug is on tap to begin dosing patients with solid tumors any day now in clinical trials at the vaunted Harvard University’s Dana-Farber Cancer Institute and partner Beth Israel Deaconess Medical Center.  Second, Cellceutix has reported that Beth Israel Read More

Cellceutix Corporation (OTCBB:CTIX) continues to align itself with the biggest names in oncology research in the world.  This truly sets the company apart from most of it developmental peers, regardless of exchange-listing or size.  The company has released news recently about FDA document submissions seeking guidance on 505(b)(2) clearance for its psoriasis drug (which has provider stellar pre-clinical data) in addition to the clinical trials for its flagship cancer drug, Kevetrin™, which should be starting at Dana-Farber in the coming months. Read More

Cellceutix Corporation (OTCBB:CTIX) has filed its Investigational New Drug (IND) application for Kevetrin™, a novel anti-cancer drug, with the U.S. Food and Drug Administration (FDA). The Company must now wait 30 calendar days before initiating Read More